文献速递肝病消化道肿瘤与早癌

抗丁型肝炎病毒阳性个体中肝细胞癌及肝脏相关事件的预测

Prediction of Hepatocellular Carcinoma and Liver-related Events in Anti-hepatitis D Virus-positive Individuals.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-10-09

多中心回顾性队列研究纳入荷兰与英国269例抗-HDV阳性者,中位随访4.3年,47例首次事件。整体5年HCC和肝脏相关事件累积发生率分别为3.8%和15.6%。无肝硬化者分别为0%和0.9%,肝硬化者为12%和41.3%(P<.001)。低PAGE-B评分者分别为0%和2.1%,中危为3.2%和21.1%,高危为25.4%和45.5%(P<.001)。Fibrosis-4评分结果类似。

要点

  • 无肝硬化者5年HCC累积发生率为0%,肝脏相关事件为0.9%。
  • 肝硬化者5年HCC累积发生率为12%,肝脏相关事件为41.3%。
  • 低PAGE-B评分者5年HCC和肝脏相关事件发生率低,可用于指导HCC监测。

核心结论

  • 抗-HDV阳性个体肝脏相关不良结局风险高。
  • 无肝硬化及基线PAGE-B和/或Fibrosis-4评分低者HCC发生率可忽略,这些评分可用于指导HCC监测策略并可能用于治疗优先排序。

研究设计与样本

  • 多中心回顾性队列研究,纳入荷兰与英国管理中心269例抗-HDV阳性个体,中位随访4.3年。

主要发现

  • 整体5年HCC累积发生率为3.8%,肝脏相关事件累积发生率为15.6%,共47例首次事件。
  • 无肝硬化者5年HCC和肝脏相关事件累积发生率分别为0%和0.9%,肝硬化者分别为12%和41.3%(P<.001)。
  • 低PAGE-B评分者5年HCC和肝脏相关事件累积发生率分别为0%和2.1%,中危者为3.2%和21.1%,高危者为25.4%和45.5%(P<.001)。
  • Fibrosis-4评分结果类似,且无论有无肝硬化或HDV RNA是否可检测,结果一致(P<.001)。

关键数值与推荐

  • 5年HCC累积发生率:无肝硬化0% vs 肝硬化12%(P<.001)。
  • 5年肝脏相关事件累积发生率:无肝硬化0.9% vs 肝硬化41.3%(P<.001)。
  • 5年HCC累积发生率:低PAGE-B评分0% vs 中危3.2% vs 高危25.4%(P<.001)。
  • 5年肝脏相关事件累积发生率:低PAGE-B评分2.1% vs 中危21.1% vs 高危45.5%(P<.001)。

临床怎么用

  • 作者认为PAGE-B和/或Fibrosis-4评分可用于指导HCC监测策略,并可能用于治疗优先排序。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic hepatitis D (CHD) is the most severe form of chronic viral hepatitis, with a high risk of developing hepatocellular carcinoma (HCC) and liver-related mortality. Risk stratification is needed to guide HCC surveillance strategies and to prioritize treatment with antiviral agents. METHODS: We conducted a multicenter retrospective cohort of anti-hepatitis D virus (HDV)-positive individuals managed at sites in the Netherlands and the United Kingdom. We studied the 5-year cumulative incidences of HCC and liver-related events (first of HCC, liver transplantation, and liver-related mortality), in the overall cohort and among relevant subgroups. RESULTS: We analyzed 269 anti-HDV-positive individuals with a median follow-up of 4.3 years in which 47 first events occurred. The 5-year cumulative incidences of HCC and liver-related events were 3.8% and 15.6% in the overall cohort. The 5-year cumulative incidence of HCC and liver-related events for individuals without cirrhosis was 0% and 0.9% compared with 12% and 41.3% for individuals with cirrhosis (P < .001). The 5-year cumulative incidence of HCC and liver-related events was 0% and 2.1% among individuals with low PAGE-B scores, compared to 3.2% and 21.1% with intermediate and 25.4% and 45.5% with high-risk scores (P < .001). We found comparable results for the Fibrosis-4 score. Findings were consistent regardless of cirrhosis or detectable HDV RNA (P < .001). CONCLUSIONS: Anti-HDV-positive individuals are at high risk of adverse liver-related outcomes. The incidence of HCC was negligible among individuals without cirrhosis and among individuals with low baseline PAGE-B and/or Fibrosis-4 scores. Therefore, these scores can be used to guide HCC surveillance strategies and potentially also for treatment prioritization.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Patmore LA, Spaan M, Agarwal K, et al. Prediction of Hepatocellular Carcinoma and Liver-related Events in Anti-hepatitis D Virus-positive Individuals. Clin Gastroenterol Hepatol. 2024. PMID: 39384029. doi:10.1016/j.cgh.2024.08.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。